PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study-Reference-Cited by-同舟云学术

PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study

Published:2017-10-06 Issue:58 Volume:8 Page:98524-98532
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Kim Hyojin¹,Kwon Hyun Jung¹,Park Soo Young¹,Park Eunhyang¹,Chung Jin-Haeng¹²

Affiliation:

1. Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea

2. Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation;Archives of Pathology & Laboratory Medicine;2024-04-16

2. Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation;Journal of Oncology Pharmacy Practice;2024-04-05

3. Principles of Analytic Validation of Immunohistochemical Assays: Guideline Update;Archives of Pathology & Laboratory Medicine;2024-02-23

4. Deep Learning for Lung Cancer Diagnosis, Prognosis and Prediction Using Histological and Cytological Images: A Systematic Review;Cancers;2023-08-05

5. In Reply: Programmed Death-Ligand 1 (PD-L1) Immunohistochemistry Calibration;Modern Pathology;2023-02